Edwards Lifesciences Corp (EW)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Edwards Lifesciences Corp (EW)
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Key Insights
Critical company metrics and information
Share Price
$73.36Market Cap
$43.27 BillionTotal Outstanding Shares
589.80 Million SharesTotal Employees
19,800Dividend
No dividendIPO Date
April 3, 2000SIC Description
Orthopedic, Prosthetic & Surgical Appliances & SuppliesHomepage
https://www.edwards.com
Historical Stock Splits
If you bought 1 share of EW before May 28, 2010, you'd have 12 shares today.
Execution Date | Split Amount |
---|---|
June 1, 2020 | 3-for-1 |
December 14, 2015 | 2-for-1 |
May 28, 2010 | 2-for-1 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $2.29 Billion |
Net Cash Flow From Investing Activities, Continuing | $2.90 Billion |
Net Cash Flow From Operating Activities | $806.40 Million |
Net Cash Flow From Operating Activities, Continuing | $806.40 Million |
Exchange Gains/Losses | $-15.80 Million |
Net Cash Flow From Investing Activities | $2.90 Billion |
Net Cash Flow | $2.27 Billion |
Net Cash Flow From Financing Activities | $-1.42 Billion |
Net Cash Flow From Financing Activities, Continuing | $-1.42 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss | $4.16 Billion |
Costs And Expenses | $4.56 Billion |
Basic Average Shares | $1.20 Billion |
Selling, General, and Administrative Expenses | $1.96 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Revenues | $6.31 Billion |
Gross Profit | $4.84 Billion |
Other Operating Expenses | $110.20 Million |
Diluted Earnings Per Share | $6.90 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Average Shares | $1.20 Billion |
Net Income/Loss Attributable To Parent | $4.16 Billion |
Research and Development | $1.13 Billion |
Cost Of Revenue | $1.48 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $4.16 Billion |
Income/Loss From Continuing Operations After Tax | $1.56 Billion |
Income Tax Expense/Benefit | $187.90 Million |
Income/Loss From Continuing Operations Before Tax | $1.75 Billion |
Operating Expenses | $3.21 Billion |
Basic Earnings Per Share | $6.92 |
Benefits Costs and Expenses | $4.56 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $-3.80 Million |
Operating Income/Loss | $1.64 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Assets | $5.51 Billion |
Other Current Liabilities | $1.46 Billion |
Equity | $9.61 Billion |
Other Non-current Assets | $3.61 Billion |
Noncurrent Assets | $6.24 Billion |
Current Liabilities | $1.94 Billion |
Prepaid Expenses | $114.90 Million |
Assets | $12.97 Billion |
Equity Attributable To Parent | $9.55 Billion |
Inventory | $1.10 Billion |
Current Assets | $6.73 Billion |
Accounts Payable | $172.80 Million |
Wages | $312.10 Million |
Liabilities And Equity | $12.97 Billion |
Equity Attributable To Noncontrolling Interest | $65.80 Million |
Liabilities | $3.36 Billion |
Noncurrent Liabilities | $1.42 Billion |
Fixed Assets | $1.68 Billion |
Intangible Assets | $956.10 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Edwards Lifesciences Corp (EW)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.